CIP2A and lung carcinoma: An analysis of cell lines of the Genomics of Drug Sensitivity in Cancer database [39], however, revealed a significant correlation of CIP2A expression levels and the gefitinib and erlotinib sensitivity, which was significant for gefitinib when the analysis was restricted to lung cancer cell lines (Supplementary Figure S3).